CBmed GmbH’s Post

Personally motivated by his own family experience with cancer, Dr. Eugene Koay has dedicated his career to unravelling some of the mysteries of pancreatic cancer. Dr. Koay, Professor of GI Radiation Oncology at The University of Texas MD Anderson Cancer Center is the lead researcher on an innovative study funded by Pancreatic Cancer North America that is harnessing artificial intelligence for the early detection of pancreatic cancer. “What excites me about this research is the opportunity to make real progress against a very deadly disease. It’s also thrilling to work at the cutting edge, as no other research currently combines this specific set of biomarkers with medical imaging. For the first time, we’ll be able to explore how these tools and technologies can improve outcomes for patients at risk.” Learn more about this cutting-edge research and how it could dramatically change survival rates for pancreatic cancer by advancing our knowledge about early detection: https://lnkd.in/giJNU9K5 #pancreaticcancerawarenessmonth #survivalnotsympathy #pancreaticcancer #cancerresearch

Personally motivated by his own family experience with cancer, Dr. Eugene Koay has dedicated his career to unravelling some of the mysteries of pancreatic cancer. Dr. Koay, Professor of GI Radiation Oncology at The University of Texas MD Anderson Cancer Center is the lead researcher on an innovative study funded by Pancreatic Cancer Canada that is harnessing artificial intelligence for the early detection of pancreatic cancer. “What excites me about this research is the opportunity to make real progress against a very deadly disease. It’s also thrilling to work at the cutting edge, as no other research currently combines this specific set of biomarkers with medical imaging. For the first time, we’ll be able to explore how these tools and technologies can improve outcomes for patients at risk.” Learn more about this cutting-edge research and how it could dramatically change survival rates for pancreatic cancer by advancing our knowledge about early detection: https://lnkd.in/gG6zyem8 #pancreaticcancerawarenessmonth #survivalnotsympathy #pancreaticcancer #cancerresearch

🚀 I am excited to announce the publication of our new article as part of the Special Issue "Liquid Biopsy for Lung Cancer Treatment" in the journal Cancers! 📝 Our article, titled "The Evidence Base for Circulating Tumor DNA-Methylation in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis", explores the use of circulating tumor DNA (ctDNA) methylation for the diagnosis and monitoring of non-small cell lung cancer (NSCLC). We conducted a systematic review and meta-analysis of existing literature, finding that this methodology is accurate and reliable, showing great promise for early diagnosis and better management of NSCLC patients. 🔬 This study represents a rigorous review and meta-analysis of existing data, made possible through the collaboration with an exceptional team of researchers. I would like to specifically thank the Cancer Genomics & Systems Biology team: Angela Rina, Diletta Rosati, Viola Bianca Serio, Elisa Frullanti, and Maria Palmieri for their dedication and support. Additionally, a sincere thank you to all the other co-authors who contributed by providing their original data, allowing us to complete this meta-analysis. 📖 The article is available online at the following links: Website: https://lnkd.in/eiMkcxVx PDF Version: https://lnkd.in/eEKgHMPX #research #science #innovation #collaboration #publication #cancer #liquidbiopsy #NSCLC #ctDNA

Day 2 at Brisbane's Annual Cancer Conference 🔬 Another fantastic day filled with cutting-edge talks on cancer research and treatment innovations. Topics ranged from the use of 3D models to study cancer, to breakthroughs in immunotherapy, and even how AI can predict tumour mutations from pathology slides. A few standout sessions for me: Prof Carlos Salomon shared groundbreaking insights on how circulating extracellular vesicles from ovarian tumour cells could serve as early biomarkers for ovarian cancer detection. Fascinating potential for improving early diagnosis! Mitchell Mostina presented his work on a new protocol that enhances vascularisation in human skin organoids, making them more representative of real human skin—an exciting advancement for organoid research. Christanny Schmidt delivered a great talk on how the microtubule cytoskeleton and Golgi apparatus interact during cell migration through tight spaces—shedding light on complex cellular processes that could be crucial for cancer metastasis. Having recently relocated to Brisbane from the UK, this conference has been an invaluable experience. It’s been a fantastic opportunity to explore the diverse range of research happening within the local scientific community. I’m excited to be part of such a vibrant and innovative network! #CancerResearch #Innovation #Immunotherapy #OvarianCancer #Organoids #CellBiology

Researchers have developed an NKG2A/NKG2C (A/C) switch molecule that converts suppressive signals from HLA-E on cancer cells into activating signals for T and NK cells, enabling them to eliminate tumors while sparing normal cells with low HLA-E expression https://lnkd.in/eZPatdmN The A/C switch-transduced T and NK cells show strong cytotoxicity against tumors with high HLA-E levels, leading to reduced tumor burden and improved survival in vivo. This approach offers a promising strategy to enhance cellular therapies like CAR T-cell therapy by selectively targeting HLA-E-overexpressing tumors while minimizing damage to normal tissues. Michelle Sætersmoen ∙ Ivan S. Kotchetkov ∙ Lamberto Torralba-Raga, Ph.D. ∙ Jorge Mansilla-Soto ∙ Ebba Sohlberg ∙ Silje Zandstra Krokeide ∙ Quirin Hammer ∙ Michel Sadelain ∙ Karl-Johan Malmberg Universitetet i Oslo Oslo University Hospital Memorial Sloan Kettering Cancer Center Karolinska Institutet H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC #Immunotherapy #CancerResearch #HLAE #CellularTherapy #ACSwitch #NKCells #TCells

Transforming Cancer Research with ViewnVivo®   Cancer research demands innovative tools to unlock its complexities. Optiscan’s ViewnVivo® is at the forefront, revolutionizing how researchers study cancer. This miniaturized hand-held confocal endomicroscope captures live, in vivo images at submicron resolution, enabling real-time observation of tumor growth and cellular interactions.   Witness the dynamic dance of cancer cells, deconstruct its intricate architecture, and explore previously unreachable areas with ViewnVivo®. This technology not only enhances our understanding but also accelerates the development of targeted therapies.   Join us in advancing cancer research with ViewnVivo®. How can this technology accelerate your research?   #CancerResearch #ViewnVivo #Optiscan #InVivoImaging #InnovativeTechnology #ResearchBreakthrough Optiscan Imaging Ltd

Pink October: Together for Breast Cancer Awareness! This month, we unite to raise awareness for Pink October, an international campaign dedicated to increasing understanding, early detection, and support for breast cancer. 💖 As the Principal Investigator of the IMPACT project, our research group at the University of Malta is deeply engaged in breast cancer research. The Laboratory of Molecular Oncology (Department of Pathology) is proud to have contributed to the field with 4 PhD graduates who focused on novel biomarkers, disease mechanisms, therapy resistance, and disease heterogeneity. Currently, 2 PhD candidates are working on tumour invasion and novel isoforms linked to aggressive breast cancer. Cancer research is a challenging yet essential endeavour, and we remain committed to making a difference in the fight against breast cancer. #PinkOctober #BreastCancerAwareness #BreastCancerResearch #IMPACTProject #CancerResearch #EarlyDetection #TogetherWeFight #SupportTheCause #PhDResearch #InnovationInHealthcare

Paper alert! 📢 Tumor cells often upregulate HLA-E to evade immune detection, making it difficult for the immune system to mount an effective response. In our latest publication, we present a groundbreaking A/C Switch receptor that empowers engineered effector cells to target and eliminate HLA-E expressing tumor cells, overcoming this critical immune-evasion strategy. With robust in vitro and in vivo data, we show that this approach is effective against both liquid and solid tumors, offering new hope in the fight against cancer. 💥 This exciting work, carried out alongside Michelle Sætersmoen and Ivan Kotchetkov, was made possible through collaboration with Michel Sadelain’s group at Memorial Sloan Kettering Cancer Center. Big thanks to everyone involved: Precision Immunotherapy Alliance, PRIMA Oslo University Hospital Universitetet i Oslo. Link: https://lnkd.in/dn7Ee_ca Stay tuned as we continue to explore innovative solutions for cancer immunotherapy! 🚀 #CancerResearch #Immunotherapy #NKG2A #NKG2C #NKCells #TumorTargeting

Pink October: Together for Breast Cancer Awareness! This month, we unite to raise awareness for Pink October, an international campaign dedicated to increasing understanding, early detection, and support for breast cancer. 💖 As the Principal Investigator of the IMPACT project, our research group at the University of Malta is deeply engaged in breast cancer research. The Laboratory of Molecular Oncology (Department of Pathology) is proud to have contributed to the field with 4 PhD graduates who focused on novel biomarkers, disease mechanisms, therapy resistance, and disease heterogeneity. Currently, 2 PhD candidates are working on tumour invasion and novel isoforms linked to aggressive breast cancer. Cancer research is a challenging yet essential endeavour, and we remain committed to making a difference in the fight against breast cancer. #PinkOctober #BreastCancerAwareness #BreastCancerResearch #IMPACTProject #CancerResearch #EarlyDetection #TogetherWeFight #SupportTheCause #PhDResearch #InnovationInHealthcare

Understanding the Hidden Truths of Cancer: CDK9's Role Revealed! Dive into the groundbreaking Italy-USA collaborative research shedding light on CDK9's pivotal function in tumor growth and DNA repair. Led by Dr. Antonio Giordano of the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University, along with the National Cancer Institute of Naples Pascale Foundation, this study, featured in 'Oncogene', opens new avenues for cancer treatment. Discover how alterations in CDK9 expression fuel tumor growth and how targeted CDK9 inhibitors are emerging as promising therapies in clinical settings. This discovery not only adds a crucial piece to our understanding of cancer development but also paves the way for innovative pharmacological interventions that could revolutionize cancer treatment strategies. Let's spread awareness and hope as we delve deeper into the complexities of cancer biology and strive for brighter, healthier futures. Link of the News: https://bit.ly/4a0dzXy Link to the Blog: https://bit.ly/3uWG2yE In Italian: https://bit.ly/3IqXrTn www.drantoniogiordano.com | www.shro.org Antonio Giordano Sbarro Health Research Organization Temple University Università degli Studi di Siena #shro #drantoniogiordanio #antoniogiordano #FortuneItalia #sbarrohealthresearchorganization #cancerresearch #cdk9 #DNArepair #oncogene #innovationincancertreatment #CRISPR #cellcycle #tumorgrowth #CancerTherapy #biomedicalscience #innovations #ResearchBreakthrough #medicaladvancements #cellbiology #precisionmedicine